Oseltamivir-Associated Supraventricular Tachycardia in an Infant

Area of Science:

• Pediatric Pharmacology
• Infectious Diseases
• Cardiology

Background:

• Oseltamivir is a neuraminidase inhibitor used for influenza treatment and prophylaxis.
• Influenza A infection was diagnosed in a previously healthy 4-month-old infant.

Observation:

• The infant experienced a diaphoretic episode with grey and clammy appearance one hour after the first oseltamivir dose.
• Following the second oseltamivir dose, the infant developed supraventricular tachycardia (heart rate >300 bpm).

Findings:

• Oseltamivir administration was temporally associated with adverse cardiovascular events in an infant.
• The infant required adenosine treatment and drug discontinuation.

Implications:

• This case highlights potential adverse cardiovascular effects of oseltamivir in infants.
• Further investigation into oseltamivir's cardiac safety profile in pediatric populations is warranted.